Julie R. Gralow, MD and Don S. Dizon, MD Follow @drdonsdizon One of the things that gives me great pleasure professionally is the ability to travel. I have been so fortunate to have had opportunities to speak and teach nationally and internationally, to see places I probably would not have otherwise had the chance to see, and to meet colleagues from all over the world. Truth be told,…
The prognostic value of the ESAS tool is unknown in gastroesophageal cancer. This study examined the association between the ESAS score and overall surviva
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medica
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
This report examines darolutamide tolerability from extended follow-up for both the double-blind and open-label treatment periods of the phase III ARAMIS t
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with…
This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological
This article reports clinical trial results of a phase II trial assessing the efficacy of rucaparib in patients with high-risk biochemically recurrent nonmetast
The data reported here will inform treatment decision-making about the use of combination therapies that include trifluridine/tipiracil in the first-, second-,
